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Total rise Binding coefficient, Coefficient
in albumin average ± SD of
level (true = 0 022) variation(g/l) (n= 1000) (%)
3 0-01696±0-02229 131
6 0 02062±0-01086 53
9 0-02146±0 00709 33
12 0-02203±0 00537 24
15 0-02191±0 00428 20
18 0-02205 ±0 00366 17
coefficients for the three subjects are 0 019,
0-029, and 0-024 respectively. While these
show statistically significant differences (P<
0-05), they are small enough to be accounted
for by the likely differences in albumin:
globulin ratio between subjects rather than
any genuine differences in albumin binding,
for the cuffing method measures binding by
all proteins, and globulin cannot be ignored.3
The important question is whether indi-
vidual determination of a binding coefficient
by the proposed method will give a better
correction for total protein binding of calcium
than would the more straightforward use of
average population coefficients for albumin
and globulin. The within-subject coefficients
of variation for the authors' three subjects
arerage 12%, but a computer simulation of
the four-point binding method which in-
corporates the authors' coefficients of variation
for calcium and albumin analyses suggests that
even this is likely to be too favourable an
estimate. The analysis (see table) shows that
the coefficient of variation of the method is
dependent on the total rise in albumin
achieved by cuffing. With smaller albumin
rises not only is the coefficient of variation very
high but the binding coefficient tends to be
systematically underestimated. There is no
support for the authors' assumption that "if
more than two timed samples are collected
then the likelihood of analytical error causing
an erroneous regression line becomes neglig-
ible." Their proposed method appears to be
unlikely to offer a means for the more accurate
correction of calcium values.
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SIR,-We read with interest the experiences
of Dr R W Pain and his colleagues with the
tourniquet test as a means of determining
protein-bound calcium in plasma (13 Decem-
ber, p 617). They kindly cite our article from
1961 and plan to explore the possibilities of
this method. I may be able to save them time
by referring them to a later publication,'
which contains a detailed study of the tourni-
quet test and the errors involved when using
it for the determination ofprotein-bound cation
by means of in-vivo ultrafiltration.
To my knowledge Niemiro2 and Gerbrandy3
were the first to use the tourniquet test for
the purpose of determining protein-bound
calcium.
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First-aid treatment of poisoning
SIR,-In considering the emergency treatment
of the poisoned child it is perhaps fair to draw
a distinction between the management by
the full-time health workers listed in your
leading article (29 November, p 483) (doctors,
nurses, health visitors, and ambulance men)
and the part-time first-aiders mentioned by
Dr P A B Raffle and his colleagues in their
letter (10 January, p 93). The former should
have (I do not say do have) a higher standard
of training than the part-timers and are more
likely to be asked for their advice and help;
it is therefore reasonable to expect them to be
able to use syrup of ipecacuanha effectively,
as the advantages of induced emesis are
considerable. I can appreciate, however, that
voluntary first-aiders might be consulted so
infrequently that it would not be right to
train them in its use.
R H JACKSON
Children's Department,
Royal Victoria Infirmary,
Newcastle upon Tyne
Natural oestrogen replacement therapy and
blood clotting
SIR,-Dr Jean Coope and her colleagues,
reporting the results of a double-blind cross-
over trial of equine ("natural") oestrogens
against placebo in the treatment of 30
patients with menopausal symptoms (18
October, p 139) recorded raised plasma levels
of the extrinsic clotting factors VII and X
and accelerated prothrombin time after three
months' treatment with conjugated equine
oestrogens (Premarin 1-25 mg daily). We
have recently completed investigations of the
effects of both "natural" and syn.thetic
oestrogens on climacteric symptoms, blood
biodhemistry, and blood clotting in peri-
menopausal patients.' We similarly found a
significant increase in the levels of factors
X and VII and accelerated prothrombin
times in patients who had received either
conjugated equine oestrogens (1-25 mg daily)
or ethinyloestradiol (0 03 mg daily) for three
months.
However, the study of Dr Coope and her
colleagues was confined to evaluating equine
"natural" oestrogens and their findings imply
that other "natural" oestrogens might also
accelerate blood clotting factors. Such a con-
clusion would be at variance with our own
data, obtained in a double-4blind, between-
patient study over six months of the effects
of oestrone piperazine sulphate (Harmogen,
3-0 mg daily), ethinyloestradiol (0 03 mg
daily), and placebo in 60 perimenopausal
patients. At each monthly assessment tests
of blood clotting and platelet studies were
performed, of which the following are
relevant to the present communication:
prothrornbin time (BCR)2; platelet aggrega-
tion time; fibrinogen assay3; cephalin time;
and assays of factors X4 and VII.5
Of 79 patients admitted, 60 completed the
six-month trial: eight of the 19 withdrawn
developed adverse effects to the active treat-
ments and 10 patients receiving placebo
were withdrawn because of failure to control
the severity of menopausal symptoms. The
results of coagulation studies are shown in
the accompanying table. Significant increases
(P<005) in the levels of fibrinogen and
factors VII and X and acceleration (P<0 01)
in prothrombin, cephalin, and platelet
aggregation times occurred between the
second and sixth months in the ethinyl-
oestradiol group. In the oestrone piperazine
sulphate group there were no significant
changes in any of these indices at any time
during the trial. Follow-up of the 21 patients
who continued with oestrone piperazine
sulphate for a period of 18 months has not
revealed any further change in these indices.
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Medical writing
SIR,-The large attendance at the teaching
seminar on medical writing and editing held
on 14 November 1975 under the auspices of
the BM7 (29 November, p 532) reflects a
growing interest in the subject. One hopes
that this interest will also be expressed by
debate in your columns, and in the columns
of other journals, on both the technical and
the linguistic aspects of writing papers. May
I raise three points now?
First I should like to say a word in defence of
the passive voice, the use of which in medical
writing is often criticised. The ambiguous "passive
of modesty" is, admittedly, indefensible. "Ten
patients were investigated by this method" could
leave the reader in doubt as to who investigated,
the author or another worker, whereas "I investiga-
ted 10 patients" or "X investigated 10 patients" is
clear. On the other hand the passive, I submit, is
better than the active if it enables a sentence, a
Results of coagulation studies (Mean ± SD) in the three treatment groups at initial assessment and after
6 months
Oestronepiperazinesulphate Ethinyloestradiol Placebo
(n = 23) (n = 20) (n = 17)
Initial 6 months Initial 6 months Initial 6 months
Prothrombin time (s) 12-2 ± 0-31 12-4 ± 0-38 12-1 ± 0-25 11-18 + 0-48t 12-2 ± 0 37 12 2 ± 0 32
Cephalin time (s) 41-3 ± 1-6 41-3 ± 1-5 41-2 ± 1-8 33 9 + 2-5t 41-1 ± 1-7 41-3 ± 1-6
Factor VII assay (s) 12-7 ± 0-18 12 8 ± 0-19 12-6 ± 0-29 11-5 ± 0-31* 12-6 ± 0-24 12-7 ± 0-21
Factor X assay (s) 22-8 ± 0-31 22-7 ± 0-38 22-6 ± 0-31 20-4 ± 0-52* 22-8 ± 0 40 22-6 ± 0-31
Plasma fibrinogen (g/l) 2-48 ± 0 094 2-49 ± 0-081 2-49 ± 0-075 2-86 ± 0-106* 2-42 ± 0-105 2-46 ± 0 093
Platelet aggregation time (s) 632 ± 14-1 630 ± 18-3 609 ± 16-2 527 ± 22-4t 630 ± 16-0 631 + 17-1
Significant changes from initial values: *P<005, tP<0-01.
Conversion: SI to traditional uniti Fibrinogen 1 g/l = 100 mg/100 ml.
